Multiple Sclerosis Drugs - Brunei Darussalam

Brunei Darussalam

The Multiple Sclerosis Drugs market in Brunei Darussalam is predicted to achieve a revenue of US$0.66m in 2024.
Furthermore, it is anticipated that the revenue will experience a steady annual growth rate (CAGR 2024-2029) of 0.60%, leading to a market volume of US$0.68m by 2029.
In terms of global comparison, United States is expected to generate the highest revenue in the market, reaching US$11,770.00m in 2024.
Despite being a small market, Brunei Darussalam is witnessing a growing demand for innovative multiple sclerosis drugs.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Multiple Sclerosis Drugs in Brunei Darussalam has been increasing steadily in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis in Brunei Darussalam prefer drugs that are effective and have minimal side effects. They also tend to prefer drugs that are available at an affordable price.

Trends in the market: The Multiple Sclerosis Drugs market in Brunei Darussalam has been growing due to the increasing prevalence of Multiple Sclerosis in the country. This has led to an increase in the demand for drugs that can effectively treat the disease. The market has also been driven by the introduction of new drugs that are more effective and have fewer side effects. The trend towards personalized medicine has also contributed to the growth of the market, as patients are increasingly looking for drugs that are tailored to their specific needs.

Local special circumstances: Brunei Darussalam has a relatively small population, which has limited the growth of the Multiple Sclerosis Drugs market in the country. However, the government has been investing in healthcare infrastructure and has been working to improve access to healthcare services in the country. This has helped to increase awareness about Multiple Sclerosis and has led to more patients seeking treatment for the disease.

Underlying macroeconomic factors: The economy of Brunei Darussalam has been growing steadily in recent years, which has led to an increase in healthcare spending in the country. This has helped to support the growth of the Multiple Sclerosis Drugs market in the country. The government has also been working to diversify the economy away from oil and gas, which has helped to create new opportunities for businesses in the healthcare sector.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.